RMDResMed

$230.03-15% 1Y
Latest close: back above its 200-day averageOct 9, 2026what changed →

Is the business good?

Excellent

A genuinely good business: 7 of 9 health tests passed, earnings fully cash-backed (1.2×), and margins widening.

4 good
Fundamental health (F-score)7 / 9SEC EDGAR · Jun 30, 2026

High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash1.21×derived · Jun 30, 2026

Operating profit is fully backed by cash.

Margin direction, 3 years+6.5 pts

Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.

Where ROE comes from17% ROA

High-quality, exceptional returns on the assets themselves, not leverage. ROE 23% = margin × turnover × leverage.

Unless marked, from derived.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversionmiddle of the market
Leverage (Debt/EBITDA)top 8% of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is RMD?

ResMed earns 26% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.

26%

Return on invested capital · cost of capital 9.0% · 17 points above what the capital costs: growth creates value

Operating margin
33%

Operating margin · Medical Instruments & Supplies median 6.6% · 12 months to Q4 2026

Cash conversion
1.21×

Cash conversion · 1.25× a year ago · operating cash flow covers the operating profit after tax

R&D as % of revenue
6.7%

R&D as % of revenue

Operating margin by fiscal year
YearOperating margin
FY202128%
FY202228%
FY202327%
FY202428%
FY202533%
FY202633%
Details›
Gross margin12 months to Q4 2026
61%
Operating margin12 months to Q4 2026
33%
Net margin12 months to Q4 2026
27%
Free cash flow margin
29%
R&D as % of revenue
6.7%
Revenue, trailing twelve months
$5.65B
Free cash flow, trailing twelve months
$1.65B
Net income, trailing twelve months
$1.52B
Return on invested capitaloperating profit after tax ÷ debt + equity − cash
26%

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.